(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 April 2023 (13.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/057985 A1

(51) International Patent Classification:
A61P 35/00 (2006.01) *A61K 31/496* (2006.01)
C07D 471/04 (2006.01) *A61K 31/4545* (2006.01)
A61K 31/5377 (2006.01) *A61K 31/4375* (2006.01)

(21) International Application Number:
PCT/IB2022/059630

(22) International Filing Date:
07 October 2022 (07.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202141046053 08 October 2021 (08.10.2021) IN
63/308,727 10 February 2022 (10.02.2022) US

(71) Applicant: **VRISE THERAPEUTICS, INC.** [US/US]; Harvard Square, One Mifflin Pl., Ste 400, Cambridge, Massachusetts 02138 (US).

(72) Inventors: **BHAVAR, Prashant Kashinath**; Harvard Square, One Mifflin Pl, Ste 400, Cambridge, Massachusetts 02138 (US). **KSHIRSAGAR, Anuj Ramesh**; c/o VeGen Therapeutics Pvt Ltd., 7TH Floor, South Wing, Krishe Sapphire, Madhapur Village, Hyderabad, Telangana 500081 (IN). **SARMA, Partha Pratim**; c/o VeGen Therapeutics Pvt Ltd., 7TH Floor, South Wing, Krishe Sapphire, Madhapur Village, Hyderabad, Telangana 500081 (IN). **GANDHAM, Adilakshmi**; c/o VeGen Therapeutics Pvt Ltd., 7TH Floor, South Wing, Krishe Sapphire, Madhapur Village, Hyderabad, Telangana 500081 (IN). **SURAMPUDI, Uday Kumar**; Harvard Square, One Mifflin Pl., Ste 400, Cambridge, Massachusetts 02138 (US).

(74) Agent: **TUNGATURTHI, Parithosh Kumar**; 8793 Manahan Drive, Ellicott City, Maryland 21043 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2023/057985 A1

(54) Title: SMALL MOLECULES FOR TREATEMENT OF CANCER



(A)

(57) Abstract: The present application relates to novel compounds described herein, the method of preparing the same, its pharmaceutical composition and method for use thereof. In particular the invention relates to compounds of formula (A) or their pharmaceutically acceptable salts thereof as inhibitors of KRAS protein and useful in treatment, prevention and/or amelioration of diseases or disorders associated with KRAS especially the Cancer.